Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 7,328.7 | 7,755.3 | 7,795.0 | 7,710.2 | 8,121.7 | 9,503.2 | 9,016.0 | 9,274.7 |
| Revenue growth | -5.5% | -0.5% | 1.1% | -5.1% | -14.5% | 5.4% | -2.8% | -4.5% |
| Cost of goods sold | 5,888.9 | 6,100.0 | 5,977.0 | 5,722.1 | 6,147.3 | 7,829.7 | 7,161.7 | 7,179.4 |
| Gross profit | 1,439.7 | 1,655.3 | 1,818.1 | 1,988.1 | 1,974.4 | 1,673.5 | 1,854.3 | 2,095.3 |
| Gross margin | 19.6% | 21.3% | 23.3% | 25.8% | 24.3% | 17.6% | 20.6% | 22.6% |
| Sales and marketing | 1,327.9 | 1,403.2 | 1,346.4 | 1,347.8 | 1,379.3 | 1,355.1 | 1,337.7 | 1,419.5 |
| General and administrative | 301.4 | 277.7 | 307.8 | 342.6 | 350.3 | 288.7 | 310.5 | 413.0 |
| EBITA | -179.9 | -7.4 | 163.9 | 278.8 | 225.9 | 15.6 | 185.5 | 258.9 |
| EBITA margin | -2.5% | -0.1% | 2.1% | 3.6% | 2.8% | 0.2% | 2.1% | 2.8% |
| Amortization of intangibles | 20.6 | 20.5 | 20.7 | 20.8 | 21.7 | 2.9 | 3.7 | 3.8 |
| EBIT | -200.5 | -27.8 | 143.1 | 258.1 | 204.3 | 12.7 | 181.9 | 255.1 |
| EBIT margin | -2.7% | -0.4% | 1.8% | 3.3% | 2.5% | 0.1% | 2.0% | 2.8% |
| Pre-tax income | -509.9 | -374.5 | 21.2 | 202.7 | -13.3 | -52.3 | 283.0 | 111.8 |
| Income taxes | -9.2 | -42.3 | -26.2 | 82.0 | -5.2 | -32.1 | -42.3 | 87.9 |
| Tax rate | 1.8% | 11.3% | | 40.5% | 39.3% | 61.4% | | 78.7% |
| Earnings from continuing ops | -499.9 | -664.0 | 50.3 | 241.2 | -7.4 | -19.6 | 325.4 | 21.8 |
| Earnings from discontinued ops | -0.1 | 4.9 | 11.3 | -0.7 | -1.1 | -0.7 | 494.0 | 139.3 |
| Net income | -499.9 | -659.1 | 61.6 | 240.5 | -8.5 | -20.3 | 819.4 | 161.0 |
| Net margin | -6.8% | -8.5% | 0.8% | 3.1% | -0.1% | -0.2% | 9.1% | 1.7% |
| |
| Diluted EPS | ($5.45) | ($7.27) | $0.55 | $2.64 | ($0.08) | ($0.21) | $3.43 | $0.23 |
| Shares outstanding (diluted) | 91.8 | 91.3 | 91.3 | 91.5 | 93.3 | 93.9 | 94.8 | 93.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|